Related Experiment Video
Updated: Mar 7, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.1K
Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction
Marty C Tam1, Ran Lee1, Thomas M Cascino1
1Frankel Cardiovascular Center, University of Michigan Health System, Ann Arbor, MI, USA.
Current Hypertension Reports
|February 25, 2017
Summary
Heart failure with preserved ejection fraction (HFpEF) is complex, with emerging models linking it to inflammation from comorbidities like hypertension (HTN). Current treatments focus on managing HTN, but tailored therapies for HFpEF subgroups are needed.
Area of Science:
- Cardiology
- Internal Medicine
- Pathophysiology
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a common condition with unclear mechanisms.
- Traditional views focus on hypertension (HTN)-induced left ventricular hypertrophy (LVH) and diastolic dysfunction.
- Emerging theories suggest systemic inflammation from comorbidities like HTN drives HFpEF.
Purpose of the Study:
- To review current understanding of HFpEF pathophysiology.
- To discuss the role of hypertension in HFpEF development and management.
- To explore current and future therapeutic strategies for HFpEF.
Main Methods:
- Literature review of HFpEF pathophysiology and treatment.
- Analysis of traditional and emerging models of HFpEF.
- Discussion of antihypertensive therapies and non-pharmacologic interventions.
Main Results:
- HFpEF is heterogeneous, influenced by factors beyond LVH, including ventricular stiffness and microvascular function.
- Treating systemic HTN is crucial, potentially regressing LVH and improving diastolic function.
- No current therapies offer definitive mortality benefits in HFpEF, though non-pharmacologic approaches may improve morbidity.
Conclusions:
- HFpEF management requires addressing systemic inflammation and comorbidities.
- Tailoring antihypertensive therapies to specific HFpEF phenotypes may be key.
- Future research should focus on identifying effective treatments for subgroups, prioritizing symptom improvement and exercise capacity over mortality reduction.
Related Concept Videos
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:30Heart Failure V: Medical Management
441
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:27Heart Failure I: Introduction
1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K